Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
Pre-publication versions of this article are available by contacting email@example.com.
|11 Aug 2017||Submitted||Original manuscript|
|21 Sep 2017||Author responded||Author comments - Thomas Ettrich|
|Resubmission - Version 2|
|21 Sep 2017||Submitted||Manuscript version 2|
|5 Jun 2018||Reviewed||Reviewer Report - Jean Luc Van Laethem|
|26 Jun 2018||Reviewed||Reviewer Report - Somnath Mukherjee|
|18 Aug 2018||Author responded||Author comments - Thomas Ettrich|
|Resubmission - Version 3|
|18 Aug 2018||Submitted||Manuscript version 3|
|4 Dec 2018||Editorially accepted|
|29 Dec 2018||Article published||10.1186/s12885-018-5183-y|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.